Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Pembrolizumab |
| Indication/Tumor Type | malignant mesothelioma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | malignant mesothelioma | predicted - sensitive | Pembrolizumab | Clinical Study | Actionable | In a clinical study, 80% (4/5) of MSLN positive mesothelioma patients with CD274 (PD-L1) expression who had progressed on LMB-100 demonstrated an objective response when treated with Keytruda (pembrolizumab), and compared to patients without CD274 expression (n=5), treatment significantly prolonged median progression-free survival (11.3 vs 2.1 mos, p<0.0018) but not overall survival (27.2 vs 6.8 mos, p=0.1) (PMID: 32611684). | 32611684 |
| CD274 positive | malignant mesothelioma | predicted - sensitive | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in a partial response in 2 pediatric patients with CD274 (PD-L1)-positive mesothelioma (PMID: 31812554; NCT02332668). | 31812554 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (31812554) | Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. | Full reference... |
| (32611684) | Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. | Full reference... |